Immunic (IMUX) Competitors $1.30 -0.10 (-6.79%) (As of 12:03 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IMUX vs. SLRN, AURA, AQST, AKBA, GHRS, CGC, KALV, FHTX, TNGX, and ALMSShould you be buying Immunic stock or one of its competitors? The main competitors of Immunic include Acelyrin (SLRN), Aura Biosciences (AURA), Aquestive Therapeutics (AQST), Akebia Therapeutics (AKBA), GH Research (GHRS), Canopy Growth (CGC), KalVista Pharmaceuticals (KALV), Foghorn Therapeutics (FHTX), Tango Therapeutics (TNGX), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry. Immunic vs. Acelyrin Aura Biosciences Aquestive Therapeutics Akebia Therapeutics GH Research Canopy Growth KalVista Pharmaceuticals Foghorn Therapeutics Tango Therapeutics Alumis Immunic (NASDAQ:IMUX) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings. Does the media favor IMUX or SLRN? In the previous week, Immunic had 12 more articles in the media than Acelyrin. MarketBeat recorded 17 mentions for Immunic and 5 mentions for Acelyrin. Acelyrin's average media sentiment score of 1.11 beat Immunic's score of 0.61 indicating that Acelyrin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acelyrin 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate IMUX or SLRN? Immunic presently has a consensus price target of $11.80, indicating a potential upside of 804.21%. Acelyrin has a consensus price target of $11.40, indicating a potential upside of 165.73%. Given Immunic's stronger consensus rating and higher probable upside, equities analysts plainly believe Immunic is more favorable than Acelyrin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunic 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Acelyrin 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has better earnings and valuation, IMUX or SLRN? Acelyrin is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunicN/AN/A-$93.61M-$1.23-1.06AcelyrinN/AN/A-$381.64M-$2.46-1.74 Do insiders & institutionals have more ownership in IMUX or SLRN? 51.8% of Immunic shares are owned by institutional investors. Comparatively, 87.3% of Acelyrin shares are owned by institutional investors. 3.0% of Immunic shares are owned by insiders. Comparatively, 13.6% of Acelyrin shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is IMUX or SLRN more profitable? Acelyrin's return on equity of -44.12% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets ImmunicN/A -169.55% -118.96% Acelyrin N/A -44.12%-39.02% Which has more risk and volatility, IMUX or SLRN? Immunic has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500. Comparatively, Acelyrin has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Does the MarketBeat Community prefer IMUX or SLRN? Immunic received 85 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 64.94% of users gave Immunic an outperform vote while only 60.00% of users gave Acelyrin an outperform vote. CompanyUnderperformOutperformImmunicOutperform Votes10064.94% Underperform Votes5435.06% AcelyrinOutperform Votes1560.00% Underperform Votes1040.00% SummaryImmunic beats Acelyrin on 11 of the 16 factors compared between the two stocks. Ad Porter & CompanyUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMUX vs. The Competition Export to ExcelMetricImmunicPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$117.55M$6.73B$5.20B$8.97BDividend YieldN/A7.94%5.23%4.04%P/E Ratio-1.064.7285.7113.39Price / SalesN/A352.931,469.4286.49Price / CashN/A22.8835.2935.09Price / Book2.045.604.914.96Net Income-$93.61M$151.32M$117.36M$224.10M7 Day Performance14.47%3.14%2.75%2.01%1 Month Performance9.66%-1.67%1.71%9.79%1 Year Performance8.75%31.88%36.01%29.97% Immunic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMUXImmunic3.4728 of 5 stars$1.31-6.8%$11.80+804.2%+16.7%$117.55MN/A-1.0670Short Interest ↓Gap UpSLRNAcelyrin2.8459 of 5 stars$4.68+2.9%$11.40+143.6%-35.0%$469.54MN/A-1.85135Short Interest ↑Positive NewsAURAAura Biosciences3.8655 of 5 stars$9.26-0.5%$23.00+148.4%+11.7%$462.55MN/A-5.3850Short Interest ↓News CoverageAQSTAquestive Therapeutics2.0219 of 5 stars$5.05-0.8%$9.80+94.1%+101.3%$460.46M$50.58M-11.31160Gap DownAKBAAkebia Therapeutics4.0738 of 5 stars$2.11+2.4%$7.50+255.5%+99.1%$460.36M$194.62M-8.96167Short Interest ↓GHRSGH Research1.3821 of 5 stars$8.80-1.5%$35.67+305.3%+35.6%$457.85MN/A-11.5210CGCCanopy Growth1.0331 of 5 stars$3.81-1.6%$3.50-8.1%-38.5%$457.68M$280.50M-0.781,029Short Interest ↑KALVKalVista Pharmaceuticals3.8817 of 5 stars$10.42+3.6%$26.00+149.5%+16.4%$450.35MN/A-2.85150Upcoming EarningsShort Interest ↑FHTXFoghorn Therapeutics3.3863 of 5 stars$8.04+0.6%$16.00+99.0%+78.8%$446.97M$25.52M-4.16120Short Interest ↓Positive NewsTNGXTango Therapeutics3.4824 of 5 stars$3.80-3.6%$13.14+245.9%-49.9%$408.19M$43.38M-3.2190Positive NewsALMSAlumisN/A$8.54-7.8%$26.83+214.2%N/A$403.28MN/A0.00N/A Related Companies and Tools Related Companies Acelyrin Alternatives Aura Biosciences Alternatives Aquestive Therapeutics Alternatives Akebia Therapeutics Alternatives GH Research Alternatives Canopy Growth Alternatives KalVista Pharmaceuticals Alternatives Foghorn Therapeutics Alternatives Tango Therapeutics Alternatives Alumis Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMUX) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
